BioCentury
ARTICLE | Clinical News

INCB18424 meets psoriasis endpoint

September 22, 2009 1:11 AM UTC

Incyte Corp. (NASDAQ:INCY) said all three doses of INCB18424 met the primary endpoint of significantly reducing total lesion score, as measured by erythema, scaling and thickness, compared to placebo ...